FY2025 Earnings Forecast for Disc Medicine Issued By Wedbush

by · The Cerbat Gem

Disc Medicine, Inc. (NASDAQ:IRON – Free Report) – Stock analysts at Wedbush cut their FY2025 earnings per share (EPS) estimates for shares of Disc Medicine in a research report issued to clients and investors on Thursday, November 6th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($6.07) for the year, down from their prior estimate of ($5.52). Wedbush has a “Outperform” rating and a $110.00 price objective on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share. Wedbush also issued estimates for Disc Medicine’s Q4 2025 earnings at ($1.66) EPS, Q1 2026 earnings at ($1.69) EPS, Q2 2026 earnings at ($1.64) EPS, Q3 2026 earnings at ($1.56) EPS, Q4 2026 earnings at ($1.44) EPS, FY2026 earnings at ($6.33) EPS, FY2027 earnings at ($3.74) EPS, FY2028 earnings at $0.46 EPS and FY2029 earnings at $6.97 EPS.

A number of other equities research analysts have also issued reports on IRON. Raymond James Financial lifted their target price on shares of Disc Medicine from $89.00 to $108.00 and gave the company a “strong-buy” rating in a research note on Friday, October 17th. Truist Financial lifted their price objective on Disc Medicine from $86.00 to $114.00 and gave the company a “buy” rating in a research report on Monday. Morgan Stanley boosted their target price on Disc Medicine from $90.00 to $115.00 and gave the company an “overweight” rating in a research note on Thursday, October 30th. National Bankshares set a $153.00 price target on Disc Medicine in a research note on Friday, October 17th. Finally, Stifel Nicolaus began coverage on Disc Medicine in a research note on Monday, November 3rd. They issued a “buy” rating and a $125.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $119.10.

Read Our Latest Report on IRON

Disc Medicine Stock Performance

Shares of IRON opened at $83.58 on Monday. The company has a market capitalization of $2.91 billion, a PE ratio of -15.62 and a beta of 0.79. The company has a debt-to-equity ratio of 0.05, a quick ratio of 32.11 and a current ratio of 32.11. The company’s 50 day moving average price is $72.18 and its 200 day moving average price is $60.09. Disc Medicine has a 52 week low of $30.82 and a 52 week high of $95.95.

Disc Medicine (NASDAQ:IRON – Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($1.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.29).

Insider Activity

In other news, Director Kevin Bitterman sold 70,000 shares of the stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $88.91, for a total transaction of $6,223,700.00. Following the transaction, the director owned 385,549 shares of the company’s stock, valued at approximately $34,279,161.59. This represents a 15.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last ninety days, insiders sold 218,046 shares of company stock worth $16,463,375. Corporate insiders own 3.64% of the company’s stock.

Hedge Funds Weigh In On Disc Medicine

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IRON. TD Asset Management Inc raised its position in shares of Disc Medicine by 11.7% in the third quarter. TD Asset Management Inc now owns 59,248 shares of the company’s stock valued at $3,915,000 after purchasing an additional 6,200 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in Disc Medicine by 2.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,094 shares of the company’s stock valued at $469,000 after buying an additional 138 shares during the last quarter. Vanguard Group Inc. raised its holdings in Disc Medicine by 3.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,448,059 shares of the company’s stock worth $95,688,000 after acquiring an additional 51,323 shares during the period. TimesSquare Capital Management LLC bought a new position in Disc Medicine in the 3rd quarter worth $12,038,000. Finally, Bryce Point Capital LLC acquired a new position in Disc Medicine during the 3rd quarter worth $259,000. Institutional investors and hedge funds own 83.70% of the company’s stock.

About Disc Medicine

(Get Free Report)

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.

Recommended Stories